Clinical Data ASCO26: In vivo oncology approaches continue to show promise Pharmaceutical TechnologyLilly's $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.OncologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026. Oncology Read full story Post navigation Previous: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to comeNext: ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026